Flavonoids as multi-target agents in colorectal cancer: mechanistic insights and translational nanomedicine perspectives
Abstract
Colorectal cancer (CRC) remains a major global health challenge due to treatment resistance and adverse effects of conventional chemotherapy. Flavonoids, naturally occurring polyphenolic compounds, have emerged as promising multi-target candidates for CRC therapy. This review summarizes the mechanisms, pharmacokinetic challenges, and translational strategies of major flavonoids: quercetin, apigenin, epigallocatechin gallate, luteolin, baicalein, fisetin, naringenin, and genistein. Preclinical evidence shows that these compounds inhibit CRC initiation, progression, and metastasis by modulating key oncogenic pathways. Mechanistically, flavonoids induce mitochondrial apoptosis, inhibit angiogenesis, reverse epithelial-mesenchymal transition, and resensitize chemoresistant cells to standard agents like 5-fluorouracil, oxaliplatin, and irinotecan. Despite strong preclinical efficacy, clinical translation is limited by poor bioavailability, rapid metabolism and clearance, and dependence on supraphysiological in vitro concentrations. To overcome this translational gap, nanotechnology-based delivery systems are evaluated to improve stability, tissue targeting, and therapeutic efficacy. Finally, ongoing clinical evaluations, safety profiles, and combination strategies are highlighted to guide the translation of flavonoid research into effective, personalized CRC therapies.